Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of β-thalassemia patients with transfusional iron overload

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 183-185

  Galanello, Renzo ^a  

^a Osp Regionale per le Microcitemie   (Italy)

Author keywords

Deferasirox (ICL670); Iron chelator; Iron overload; Pediatrics; thalassemia

Indexed keywords

ALANINE AMINOTRANSFERASE; CALCITONIN RECEPTOR; CHELATING AGENT; COLLAGEN TYPE 1; DEFERASIROX; DEFEROXAMINE; ESTROGEN RECEPTOR; VITAMIN D RECEPTOR;

ADULT; AMENORRHEA; ARTHROPATHY; BETA THALASSEMIA; BONE DISEASE; CARDIOMYOPATHY; CHILD; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE REGIMEN; GRANULOCYTOSIS; GROWTH DISORDER; HUMAN; HYPOGONADISM; IRON OVERLOAD; MAJOR CLINICAL STUDY; NEUROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL; THALASSEMIA MAJOR;

EID: 29744438975     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.021     Document Type: Conference Paper

References (5)

1. GALANELLO, R., A. PIGA, D. ALBERTI, et al. 2003. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J. Clin. Pharmacol. 43: 565-572.
2. CAPPELLINI, M.D., M. BEJAOUI, S. PERROTTA, et al. 2004. Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade) versus deferoxamine in patients with β-thalassemia and transfusional hemosiderosis. Blood 104(Suppl. 11): Abstr. 3619.
3. KUSHNER, J.P., J.P. PORTER & N.F. OLIVIERI. 2001. Secondary iron overload. Hematology (Am. Soc. Hematol. Educ. Program), pp. 47-61.
4. HERSHKO, C., G. LINK & I. CABANTCHIK. 1998. Pathophysiology of iron overload. Ann. N.Y. Acad. Sci. 850: 191-201.
5. BORGNA-PIGNATTI, C., S. RUGOLOTTO, P. DE STEFANO, et al. 2004. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.